Comparative cardiovascular effects of thiazolidinediones: Systematic review and meta-analysis of observational studies

BMJ

Volumn 342, Issue 7799, 2011, Pages 692-

  Loke, Yoon Kong ^a   Kwok, Chun Shing ^a   Singh, Sonal ^b  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLITAZONE DERIVATIVE; PIOGLITAZONE; ROSIGLITAZONE;

CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; DEATH; DRUG EFFICACY; DRUG SAFETY; DRUG USE; EFFECT SIZE; GEOGRAPHIC DISTRIBUTION; HEART INFARCTION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SIDE EFFECT; SYSTEMATIC REVIEW;

DIABETES MELLITUS, TYPE 2; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; MYOCARDIAL INFARCTION; PROGNOSIS; PUBLICATION BIAS; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 79953203593     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d1309     Document Type: Review

References (44)

1. Gale EA. Lessons from the glitazones: a story of drug development. Lancet 2001;357:1870-5. (Pubitemid 32539124)
2. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005;294:2581-6. (Pubitemid 41697247)
3. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010;170:1191-201.
4. Singh S, Loke YK, Furberg CD. Long-termrisk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298:1189-95. (Pubitemid 47403105)
5. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-8. (Pubitemid 47403104)
6. Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care 2007;30:2148-53. (Pubitemid 47219440)
7. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009;180:32-9.
8. Cohen D. Insiders criticise FDA's decision not to withdraw rosiglitazone. BMJ 2010;341:c5333.
9. Misbin RI. Lessons fromthe Avandia controversy: a newparadigmfor the development of drugs to treat type 2 diabetes. Diabetes Care 2007;30:3141-4. (Pubitemid 350255264)
10. Loke YK, Price D, Herxheimer A. Adverse effects. In: Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. John Wiley & Sons, 2008.
11. Davies HT, Crombie IK, Tavakoli M. When can odds ratios mislead? BMJ 1998;316:989-91.
12. Cates CJ. Dr Chris Cates EBM website. 2010. www.nntonline.net.
13. Deeks JJ, Higgins JP, Altman DG. Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. John Wiley & Sons, 2008.
14. Bilik D, McEwen LN, Brown MB, Selby JV, Karter AJ, Marrero DG, et al. Thiazolidinediones, cardiovascular disease and cardiovascular mortality: translating research into action for diabetes (TRIAD). Pharmacoepidemiol Drug Saf 2010;19:715-21.
15. Brownstein JS, Murphy SN, Golfine AB, Grant RW, Sordo M, Gainer V, et al. Rapid identification of myocardial infarction risk associated with diabetes medications using electronic medical records. Diabetes Care 2010;33:526-31.
16. Dormuth CR, Maclure M, Carney G, Schneeweiss S, Bassett K, Wright JM. Rosiglitazone and myocardial infarction in patients previously prescribed metformin. PLoS One 2009;4:e6080.
17. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worral C, et al. Risk of acute myocardial infarction, stroke, heart failure and death in Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010;304:411-8.
18. Hsiao FY, Huang WF, Wen YW, Chen PF, Kuo KN, Tsai YW. Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the national health insurance database in Taiwan. Drug Saf 2009;32:675-90.
19. Juurlink DN, Gomes T, Lipscombe LL, Austin PC, Hux JE, Mamdani MM. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ 2009;339:b2942.
20. Koro CE, Fu Q, Stender M. An assessment of the effect of thiazolidinedione exposure on the risk of myocardial infarction in type 2 diabetic patients. Pharmacoepidemiol Drug Saf 2008;17:989-96.
21. Lipscombe LL, Gomes T, Levesque LE, Hux JE, Juurlink DN, Alter DA. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007;298:2634-43. (Pubitemid 350254955)
22. Margolis DJ, Hoffstand O, Strom BL. Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiol Drug Saf 2008;17:753-9.
23. Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, et al. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol 2009;46:145-54.
24. Stockl KM, Le L, Zhang S, Harada AS. Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications. Pharmacoepidemiol Drug Saf 2009;18:166-74.
25. Tzoulaki I, Mokokhia M, Curcin V, Little MP, Millett CJ, Ng A, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009;3339:b4731.
26. Walker AM, Koro CE, Landon J. Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007. Pharmacoepidemiol Drug Saf 2008;17:760-8.
27. Wertz DA, Chang CL, Sarawate CA, Willey VJ, Cziraky MJ, Bohn RL. Risk of cardiovascular events and all-cause mortality in patients treated with thiazolidinediones in a managed-care populations. Circ Cardiovasc Qual Outcomes 2010;3:538-45.
28. Winkelmayer WC, Setoguchi S, Levin R, Solomon DH. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med 2008;168:2368-75.
29. Ziyadeh N, McAfee AT, Koro C, Landon J, Arnold Chan K. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using the US health insurance database. Clin Ther 2009;31:2665-77.
30. Lee CD, Folsom AR, Pankow JS, Brancati FL, for the Atherosclerosis Risk in Communities (ARIC) Study Investigators. Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction. Circulation 2004;109:855-60.
31. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004;27:1879.
32. Roussel R, Travert F, Pasquet B, Wilson PW, Smith SC Jr, Goto S, et al, for the Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 2010;170:1892-9.
33. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71. (Pubitemid 46919772)
34. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003;326:472.
35. Papanikolaou PN, Christidi GD, Ioannidis JPA. Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies. CMAJ 2006;174:635-41. (Pubitemid 43341873)
36. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, et al, for the GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547-54.
37. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, et al, for the PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008;299:1561-73.
38. Gerstein HC, Ratner RE, Cannon CP, Serruys PW, GarcÃa-GarcÃa HM, van Es GA, et al, for the APPROACH Study Group. Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. Circulation 2010;121:1176-87.
39. Young PW, Buckle DR, Cantello BC, Chapman H, Clapham JC, Coyle PJ, et al. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J Pharmacol Exp Ther 1998;284:751-9. (Pubitemid 28086668)
40. Zhang H, Zhang A, Kohan DE, Nelson RD, Gonzalez FJ, Yang T. Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci USA 2005;102:9406-11. (Pubitemid 40923576)
41. Health Canada. Avandia, Avandamet and Avandaryl: important new restrictions on the use of rosiglitazone products due to information on heart-related events. 2010. www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/ public/-2010/avandia-6-pc-cp-eng.php.
42. Shah ND, Montori VM, Krumholz HM, Tu K, Alexander GC, Jackevicius CA. Responding to an FDA warning - geographic variation in the use of rosiglitazone. N Engl J Med 2010;10:1056.
43. US Food and Drug Administration. FDA drug safety communication: ongoing safety review of Actos (pioglitazone) and potential increased risk of bladder cancer after two years exposure. 2010. www.fda.gov/Drugs/DrugSafety/ucm226214. htm.
44. Wang AT, McCoy CP, Murad MH, Montori VM. Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review. BMJ 2010;340:c1344.